Strategic partnerships Rhythm Biosciences has a track record of strategic partnerships and acquisitions to expand its diagnostic portfolio, notably acquiring the geneType platform and assets from Genetic Technologies and forming manufacturing partnerships with Quansys Biosciences. Target potential channel partners and distributors who can integrate ColoSTAT and geneType into existing screening and risk assessment workflows.

Colorectal focus ColoSTAT positions Rhythm as a simple, affordable colorectal cancer screening option for patients unable or unwilling to use existing modalities. Sales opportunities include health systems and screening programs seeking less invasive, cost-effective alternatives, especially in preventive care and population screening initiatives.

New risk tools The launch of geneType Cancer Risk Assessment broadens Rhythm’s offering beyond detection to risk stratification. Explore collaborations with insurers, primary care networks, and cancer prevention programs to integrate risk assessment into routine care pathways and wellness platforms.

Public listing advantage As a publicly listed company with a growing revenue base and ongoing expansion, Rhythm can leverage investor-backed credibility to secure pilot programs, government-funded screening initiatives, and consortium partnerships in regional markets seeking proven diagnostics providers.

Global expansion readiness Rhythm emphasizes working with likeminded global partners for commercialization and distribution. Identify international distributors, contract manufacturers, and integrators in high- cancer burden regions to accelerate market entry for ColoSTAT and geneType within existing diagnostic ecosystems.